Application of neferine in preparation of drugs for preventing or treating acute respiratory distress syndrome

A technology for acute respiratory distress and nexinine, which is applied in the field of application of nenoxinine in the preparation of drugs for the prevention or treatment of acute respiratory distress syndrome, and can solve the problem of acute respiratory distress syndrome that has not yet been prevented or treated by nexinine. Levy and other issues

Active Publication Date: 2017-09-08
BINZHOU MEDICAL COLLEGE
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there is no relevant report on the prevention or treatment of acute respiratory distress syndrome

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of neferine in preparation of drugs for preventing or treating acute respiratory distress syndrome
  • Application of neferine in preparation of drugs for preventing or treating acute respiratory distress syndrome
  • Application of neferine in preparation of drugs for preventing or treating acute respiratory distress syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1: Effects of nexinine on pathological changes of lung tissue, pulmonary edema and pulmonary vascular permeability.

[0060] In this example, the effect of nexinine on the pathological changes of lung tissue, pulmonary edema and pulmonary vascular permeability was detected. In this example, an ARDS mouse injury model induced by extrapulmonary factor LPS was used.

[0061] 1. Materials

[0062] C57BL / 6 mice, male, weighing 18-20 g, clean grade, were purchased from Shandong Jinan Pengyue Experimental Animal Breeding Co., Ltd. (product number: SCXK (Lu) 20140007), and were fed adaptively for 3 days (d). Drink water and eat freely. Neferine (Nef) with a purity of 98% was purchased from Shanghai Ligen Biotechnology Pharmaceutical Co., Ltd. (product number: Z118105); lipopolysaccharide (LPS) and Evans blue (Evans blue) were purchased from sigma company (product number: L2880, E2129); Total Antioxidant Capacity (T-AOC) Kit, Superoxide Dismutase (SOD) Kit, Lipid Oxi...

Embodiment 2

[0075] Example 2: Effects of nexinine on the expression of polysaccharide-coated SDC-1 and HS in the lung.

[0076] This example detects the effect of neresinine on the expression of lung polysaccharide-coated SDC-1 and HS. In this example, an ARDS mouse injury model induced by extrapulmonary factor LPS is used.

[0077] 1. Materials

[0078] C57BL / 6 mice, male, weighing 18g-20g, clean grade, were purchased from Shandong Jinan Pengyue Experimental Animal Breeding Co., Ltd. (product number: SCXK (Lu) 20140007), and were fed adaptively for 3 days (d). Drink water and eat freely. Neferine (Nef) with a purity of 98% was purchased from Shanghai Ligen Biotechnology Pharmaceutical Co., Ltd. (product number: Z118105); lipopolysaccharide (LPS); Syndecan-1 antibody was purchased from Abcam (product number: ab128936); Thrombomodulin was purchased from R&D Company (product number: AF3894); HS antibody was purchased from Swampscott Company (product number: 10E4020216); goat serum block...

Embodiment 3

[0086] Example 3: Effect of nexinine on ROS content in lung tissue.

[0087] This example detects the effect of nexinine on the ROS content in lung tissue, and the LPS-induced ARDS mouse injury model is used in this example.

[0088] Materials and methods are the same as in Example 1.

[0089] Six experimental mice in each group were killed after 6 hours (h) of LPS injection, and the lung tissue of the mice was taken at 4°C, and about 60 mg of the mouse lung tissue was weighed, and the tissue lysate was added at a ratio of 1:5. After ultrasonic homogenization, centrifuge at 13800g / 20 minutes (min), after 20 minutes (min), take 200 μL supernatant and add it to a 96-well plate, add 10 μL 2,7-dichlorofluorescein diacetate (DCFH -DA), incubated at 37°C for 30 minutes (min). In the presence of reactive oxygen species, DCFH-DA can be oxidized to produce oxidized dichlorofluorescein (DCF). The DCF fluorescence was detected by a fluorescent microplate reader at an excitation wave...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of neferine in the prevention or treatment of acute respiratory distress syndrome (ARDS). The neferine is alkaloid extracted from natural plants and has antioxidant activity. Based on the construction of animal and cell damage models of acute respiratory distress syndrome, by HE, Evan blue staining, fluorescent probe, immunofluorescence labeling and the like, it is verified that the neferine can reduce the production and release of reactive oxygen species (ROS) and reduce the degradation of vascular endothelium polysaccharide coating (Glycocalyx), thus the occurrence and development of ARDS are inhibited, and ARDS is prevented or treated.

Description

technical field [0001] The invention relates to the prevention or treatment of ARDS by inhibiting the occurrence and development of acute respiratory distress syndrome (ARDS) by nexinine. The specific mechanism of the present invention relates to the prevention or treatment of ARDS by reducing the degradation of the vascular endothelial polysaccharide coating caused by oxidative damage by inhibiting the generation and release of active oxygen by nexinine, thereby reducing vascular permeability. Background technique [0002] Acute respiratory distress syndrome (ARDS) refers to severe infection, trauma, shock, aspiration and other non-cardiac pathogenic factors, with progressive respiratory distress and refractory hypoxemia Acute respiratory failure syndrome with clinical features. The onset of ARDS is rapid and its development is rapid. There is still no effective clinical medicine to curb the progress of the disease. Therefore, the prognosis of ARDS is poor, and the mortali...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4725A61P11/00
CPCA61K31/4725
Inventor 刘向勇王晓芝徐海晓孔桂青
Owner BINZHOU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap